PL2734222T3 - Sposoby leczenia chorób układu krążenia i prognozowania skuteczności terapii ruchowej - Google Patents

Sposoby leczenia chorób układu krążenia i prognozowania skuteczności terapii ruchowej

Info

Publication number
PL2734222T3
PL2734222T3 PL12814331T PL12814331T PL2734222T3 PL 2734222 T3 PL2734222 T3 PL 2734222T3 PL 12814331 T PL12814331 T PL 12814331T PL 12814331 T PL12814331 T PL 12814331T PL 2734222 T3 PL2734222 T3 PL 2734222T3
Authority
PL
Poland
Prior art keywords
predicting
efficacy
methods
cardiovascular diseases
treating cardiovascular
Prior art date
Application number
PL12814331T
Other languages
English (en)
Inventor
James V. Snider
Robert W. Gerwien
Original Assignee
Critical Care Diagnostics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Critical Care Diagnostics, Inc. filed Critical Critical Care Diagnostics, Inc.
Publication of PL2734222T3 publication Critical patent/PL2734222T3/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
PL12814331T 2011-07-18 2012-07-18 Sposoby leczenia chorób układu krążenia i prognozowania skuteczności terapii ruchowej PL2734222T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161508923P 2011-07-18 2011-07-18
US201161509359P 2011-07-19 2011-07-19

Publications (1)

Publication Number Publication Date
PL2734222T3 true PL2734222T3 (pl) 2017-03-31

Family

ID=47558450

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12814331T PL2734222T3 (pl) 2011-07-18 2012-07-18 Sposoby leczenia chorób układu krążenia i prognozowania skuteczności terapii ruchowej

Country Status (13)

Country Link
US (5) US8748110B2 (pl)
EP (2) EP3173093B1 (pl)
JP (2) JP6134316B2 (pl)
CN (2) CN106908604B (pl)
AU (2) AU2012284039B2 (pl)
BR (1) BR112014001283A2 (pl)
CA (1) CA2842072A1 (pl)
DK (1) DK2734222T3 (pl)
ES (1) ES2611403T3 (pl)
HK (1) HK1198125A1 (pl)
MX (1) MX351428B (pl)
PL (1) PL2734222T3 (pl)
WO (1) WO2013012945A1 (pl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002038794A2 (en) 2000-11-09 2002-05-16 The Brigham And Women's Hospital, Inc. Cardiovascular disease diagnostic and therapeutic targets
CA2484897C (en) 2002-05-09 2015-10-06 The Brigham And Women's Hospital, Inc. Soluble st2 as a cardiovascular disease marker and therapeutic target
ATE476657T1 (de) 2006-04-24 2010-08-15 Critical Care Diagnostics Inc Vorhersage von letalität und detektion von schweren erkrankungen
WO2007143295A2 (en) * 2006-04-27 2007-12-13 Critical Care Diagnostics, Inc. Interleukin-33 (il-33) for the diagnosis and prognosis of cardiovascular disease
DK2482078T3 (en) 2006-05-01 2016-05-02 Critical Care Diagnostics Inc Cardiovascular disease diagnosis
ES2542343T3 (es) * 2006-05-02 2015-08-04 Critical Care Diagnostics, Inc. Diagnóstico diferencial entre enfermedad pulmonar y cardiovascular
SI3093663T1 (sl) 2008-04-18 2018-10-30 Critical Care Diagnostics, Inc. Napovedovanje tveganja večjih neželenih srčno-žilnih dogodkov
MX2012011667A (es) 2010-04-09 2013-03-05 Critical Care Diagnostics Inc Anticuerpos st-2 humanos solubles y ensayos.
JP6215713B2 (ja) 2011-03-17 2017-10-18 クリティカル ケア ダイアグノスティクス インコーポレイテッド 有害臨床転帰のリスクを予測する方法
ES2611403T3 (es) 2011-07-18 2017-05-08 Critical Care Diagnostics, Inc. Procedimientos de tratamiento de enfermedades cardiovasculares y de predicción de la eficacia de terapia de ejercicio
US20130345805A1 (en) 2012-05-18 2013-12-26 Cardiac Pacemakers, Inc. Methods for treating or predicting risk of a ventricular tachyarrhythmia event
EP3282258A1 (en) 2012-08-16 2018-02-14 Critical Care Diagnostics, Inc. Methods for predicting risk of developing hypertension
WO2014031764A1 (en) 2012-08-21 2014-02-27 Critical Care Diagnostics, Inc. Multimarker risk stratification
CN104017056B (zh) * 2014-06-27 2016-08-17 国科戎安生物科技（北京）有限公司 St2蛋白抑制剂多肽及其应用
CN104017057B (zh) * 2014-06-27 2016-08-24 榆林市第一医院 一种st2蛋白抑制剂多肽及其应用
US10670611B2 (en) 2014-09-26 2020-06-02 Somalogic, Inc. Cardiovascular risk event prediction and uses thereof
CN107109494B (zh) 2014-11-10 2023-10-27 豪夫迈·罗氏有限公司 Il-33介导型疾病的治疗方法和诊断方法
CR20170240A (es) 2014-11-10 2018-04-03 Genentech Inc Anticuerpos anti-interleucina-33 y sus usos
US10079073B2 (en) 2014-12-11 2018-09-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker
US10324089B2 (en) 2014-12-11 2019-06-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker
CN105259353B (zh) * 2015-10-15 2017-03-22 北京市心肺血管疾病研究所 一种主动脉瘤和/或主动脉夹层患者血液中可溶性st2的检测试剂盒及检测方法
EP3427653B1 (en) * 2016-04-15 2021-03-31 Omron Corporation Biological information analysis device, system, and program
BR112018071395A2 (pt) * 2016-04-18 2019-02-05 Centre Dinvestigation Clinique Plurithematique Pierre Drouin Inserm Chu De Nancy Inst Lorrain Du Coe métodos de identificação de pacientes, método de previsão do risco de progressão para lvh, método de diferenciação em pacientes, métodos de previsão se pacientes se encontram com risco de progressão para lvh e uso
CN108982871B (zh) * 2018-07-19 2021-09-24 北京市心肺血管疾病研究所 血清sST2在小儿扩张型心肌病预后中的应用
PE20230252A1 (es) 2020-03-13 2023-02-07 Genentech Inc Anticuerpos anti-interleucina-33 y sus usos de estos
RU2741195C1 (ru) * 2020-03-27 2021-01-22 Государственное бюджетное учреждение здравоохранения Нижегородской области "Нижегородская областная клиническая больница им. Н.А. Семашко" Способ прогнозирования ургентных сердечно-сосудистых осложнений при остром коронарном синдроме у больных с онкологическим заболеванием в анамнезе

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4302386A (en) 1978-08-25 1981-11-24 The Ohio State University Antigenic modification of polypeptides
US4105776A (en) 1976-06-21 1978-08-08 E. R. Squibb & Sons, Inc. Proline derivatives and related compounds
JPS533020A (en) 1976-06-29 1978-01-12 Matsushita Electric Ind Co Ltd Static picture reception unit
US4316906A (en) 1978-08-11 1982-02-23 E. R. Squibb & Sons, Inc. Mercaptoacyl derivatives of substituted prolines
IL58849A (en) 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
US4508729A (en) 1979-12-07 1985-04-02 Adir Substituted iminodiacids, their preparation and pharmaceutical compositions containing them
US4344949A (en) 1980-10-03 1982-08-17 Warner-Lambert Company Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids
ZA817261B (en) 1980-10-23 1982-09-29 Schering Corp Carboxyalkyl dipeptides,processes for their production and pharmaceutical compositions containing them
US4337201A (en) 1980-12-04 1982-06-29 E. R. Squibb & Sons, Inc. Phosphinylalkanoyl substituted prolines
US4410520A (en) 1981-11-09 1983-10-18 Ciba-Geigy Corporation 3-Amino-[1]-benzazepin-2-one-1-alkanoic acids
GB2128984B (en) 1982-05-12 1985-05-22 Hoffmann La Roche Diaza-bicyclic compounds
JPS5911218U (ja) 1982-07-14 1984-01-24 松下電器産業株式会社 燃焼器
US4816463A (en) 1986-04-01 1989-03-28 Warner-Lambert Company Substituted diimidazo [1,5-a: 4',5'-d]pyridines having antihypertensive activity
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US4772684A (en) 1987-01-20 1988-09-20 Triton Biosciences, Inc. Peptides affecting blood pressure regulation
US5081127A (en) 1988-01-07 1992-01-14 E. I. Du Pont De Nemours And Company Substituted 1,2,3-triazole angiotensin II antagonists
US5064825A (en) 1989-06-01 1991-11-12 Merck & Co., Inc. Angiotensin ii antagonists
US5073566A (en) 1989-11-30 1991-12-17 Eli Lilly And Company Angiotensin ii antagonist 1,3-imidazoles and use thereas
US5085992A (en) 1990-07-19 1992-02-04 Merck & Co., Inc. Microbial transformation process for antihypertensive products
US5087634A (en) 1990-10-31 1992-02-11 G. D. Searle & Co. N-substituted imidazol-2-one compounds for treatment of circulatory disorders
WO2002038794A2 (en) 2000-11-09 2002-05-16 The Brigham And Women's Hospital, Inc. Cardiovascular disease diagnostic and therapeutic targets
GB2372114A (en) * 2001-02-07 2002-08-14 Cardionetics Ltd A computerised physical exercise program for rehabilitating cardiac health patients together with remote monitoring
CA2484897C (en) * 2002-05-09 2015-10-06 The Brigham And Women's Hospital, Inc. Soluble st2 as a cardiovascular disease marker and therapeutic target
ATE476657T1 (de) 2006-04-24 2010-08-15 Critical Care Diagnostics Inc Vorhersage von letalität und detektion von schweren erkrankungen
WO2007143295A2 (en) 2006-04-27 2007-12-13 Critical Care Diagnostics, Inc. Interleukin-33 (il-33) for the diagnosis and prognosis of cardiovascular disease
DK2482078T3 (en) * 2006-05-01 2016-05-02 Critical Care Diagnostics Inc Cardiovascular disease diagnosis
ES2542343T3 (es) 2006-05-02 2015-08-04 Critical Care Diagnostics, Inc. Diagnóstico diferencial entre enfermedad pulmonar y cardiovascular
RU2355295C1 (ru) * 2007-10-23 2009-05-20 Федеральное Государственное Учреждение "Саратовский Научно-Исследовательский Институт Кардиологии Росмедтехнологий" Способ реабилитации больных ибс
SI3093663T1 (sl) 2008-04-18 2018-10-30 Critical Care Diagnostics, Inc. Napovedovanje tveganja večjih neželenih srčno-žilnih dogodkov
GB0818650D0 (en) * 2008-10-10 2008-11-19 Uni I Oslo Methods
ES2431358T3 (es) * 2008-11-11 2013-11-26 B.R.A.H.M.S Gmbh Pronóstico y evaluación del riesgo en pacientes que padecen insuficiencia cardíaca mediante la determinación de la concentración de ADM
MX2012011667A (es) 2010-04-09 2013-03-05 Critical Care Diagnostics Inc Anticuerpos st-2 humanos solubles y ensayos.
JP6215713B2 (ja) 2011-03-17 2017-10-18 クリティカル ケア ダイアグノスティクス インコーポレイテッド 有害臨床転帰のリスクを予測する方法
ES2611403T3 (es) 2011-07-18 2017-05-08 Critical Care Diagnostics, Inc. Procedimientos de tratamiento de enfermedades cardiovasculares y de predicción de la eficacia de terapia de ejercicio
BR112014016661A8 (pt) 2012-01-04 2017-07-04 Wellesley Pharmaceuticals Llc formulação de liberação prolongada para reduzir a frequência de urinação e método de uso da mesma
US20130345805A1 (en) 2012-05-18 2013-12-26 Cardiac Pacemakers, Inc. Methods for treating or predicting risk of a ventricular tachyarrhythmia event
EP3282258A1 (en) 2012-08-16 2018-02-14 Critical Care Diagnostics, Inc. Methods for predicting risk of developing hypertension
WO2014031764A1 (en) 2012-08-21 2014-02-27 Critical Care Diagnostics, Inc. Multimarker risk stratification
JP6655016B2 (ja) 2014-01-10 2020-02-26 クリティカル ケア ダイアグノスティクス インコーポレイテッド 心不全のリスクを決定するための方法
USD770057S1 (en) 2014-04-14 2016-10-25 Critical Care Diagnostics, Inc. Blood test kit
US10324089B2 (en) 2014-12-11 2019-06-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker
US10079073B2 (en) 2014-12-11 2018-09-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker

Also Published As

Publication number Publication date
AU2017204261A1 (en) 2017-07-13
CN103796669A (zh) 2014-05-14
CN103796669B (zh) 2016-11-09
EP2734222B1 (en) 2016-10-19
US10928393B2 (en) 2021-02-23
JP2014529059A (ja) 2014-10-30
MX2014000715A (es) 2014-02-20
AU2012284039B2 (en) 2017-03-30
CN106908604A (zh) 2017-06-30
WO2013012945A1 (en) 2013-01-24
JP6134316B2 (ja) 2017-05-24
US20190049444A1 (en) 2019-02-14
EP3173093B1 (en) 2018-12-05
HK1198125A1 (en) 2015-03-13
DK2734222T3 (en) 2017-01-30
US20140286944A1 (en) 2014-09-25
BR112014001283A2 (pt) 2017-02-21
CA2842072A1 (en) 2013-01-24
JP6416974B2 (ja) 2018-10-31
US20130071404A1 (en) 2013-03-21
CN106908604B (zh) 2019-01-29
US9551708B2 (en) 2017-01-24
AU2017204261B2 (en) 2018-09-06
US20210164976A1 (en) 2021-06-03
MX351428B (es) 2017-10-13
US20170122942A1 (en) 2017-05-04
US8748110B2 (en) 2014-06-10
JP2017194469A (ja) 2017-10-26
EP2734222A4 (en) 2015-04-15
EP2734222A1 (en) 2014-05-28
ES2611403T3 (es) 2017-05-08
AU2012284039A1 (en) 2014-02-06
EP3173093A1 (en) 2017-05-31

Similar Documents

Publication Publication Date Title
HK1198125A1 (en) Methods of treating cardiovascular diseases and predicting the efficacy of exercise therapy
IL261768B (en) Devices and methods for tissue treatment
ZA201305783B (en) Composition and methods for treating cardiovascular diseases
ZA201308111B (en) Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
PL2619576T3 (pl) Środki i sposoby do prognozowania odpowiedzi na leczenie u pacjenta chorego na nowotwór złośliwy
IL226401A0 (en) Methods for treating disorders related to @fgfBA
HK1201454A1 (en) Therapeutic agents and uses thereof
EP2858517A4 (en) TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASES AND THROMBOSIS
EP2925312A4 (en) ENTACAPONE FOR THE PREVENTION AND TREATMENT OF ADIPOSITAS AND RELATED METABOLISM DISEASES
IL230433A0 (en) Pain management methods
EP2694079A4 (en) POLYMERS AND METHOD FOR PAIN TREATMENT
IL232135A0 (en) Therapeutic combinations and methods for treating melanoma
EP2803344A4 (en) THERAPEUTIC GYMNASTIC METHOD AND THERAPEUTIC GYMNASTIC DEVICE
HK1212225A1 (en) Therapeutic formulation and methods of treatment
EP2670438A4 (en) SELECTION AND TREATMENT OF PATIENTS
EP2575824A4 (en) METHODS FOR THE TREATMENT AND PREVENTION OF INFLAMMATORY DISEASES
EP2672965A4 (en) TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASE AND THROMBOSIS
EP2750508A4 (en) COMPOUNDS AND THERAPEUTIC METHODS
EP2710017A4 (en) MACROCYCLIC THERAPEUTIC AGENTS AND METHODS OF TREATMENT
ZA201308176B (en) Therapeutic treatment
GB201113140D0 (en) Prediction and treatment of cancer
IL214194A0 (en) Training and therapy apparatus
GB201115759D0 (en) Therapeutic treatments
GB201115761D0 (en) Therapeutic treatments